Time to first treatment from diagnosis
Figure 2 · Panel Time_to_first_treatment_from_diagnosis_months_
Panel Time_to_first_treatment_from_diagnosis_months_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Deyan Y Yosifov, Sandra Robrecht, Adam Giza, Palash C Maity, Armin Riecke, Christof Schneider, Billy M C Jebaraj, Rashmi P Dheenadayalan, Hassan Jumaa, Marc Young, Manish Kumar, Lothar Müller, Ursula Vehling-Kaiser, Michael Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Petra Langerbeins, Eugen Tausch, Stephan Stilgenbauer
Hemasphere 10(6) e70385
IGLV3-21R110 is a point mutation enabling autonomous B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors. Here, we analyzed samples from the phase 3 CLL12 study that compared ibrutinib vs. placebo in untreated early-stage CLL patients with intermediate to very high risk of disease progression, while patients with low risk of disease progression were allocated to watch-and-wait (w&w). Four detection methods (targeted next-generation sequencing, Sanger sequencing, multiplex IGLV3-21R110-specific PCR, and flow cytometry) were compared, yielding highly consistent results. Overall, 34/515 (6.6%) patients had productive IGLV3-21 rearrangements: 5/152 (3.3%) in w&w, 15/181 (8.3%) in placebo, and 14/182 (7.7%) in the ibrutinib group. Of these, 25 were IGLV3-21R110-positive (3/5, 12/15, and 10/14). IGLV3-21R110 was associated with shorter event-free survival (EFS) across all arms: w&w (hazard ratio [HR] 17.03, 95% confidence interval [CI 95%]: 4.99-58.13, P < 0.001), placebo (HR 2.31, CI 95%: 1.16-4.6, P = 0.017), and ibrutinib (HR 2.99, CI 95%: 1.17-7.65, P = 0.023). Multivariable analysis identified IGLV3-21R110 as an independent prognostic factor for shorter EFS (HR 3.18, CI 95%: 1.73-5.83, P < 0.001). Notably, IGLV3-21R110 was associated with reduced clinical effectiveness of ibrutinib. Ca2+-flux and cell viability assays using patient-derived BCRs expressed in murine B-cells confirmed reduced ibrutinib efficacy in IGLV3-21R110 cases, especially regarding inhibition of antigen-stimulated signaling. In summary, IGLV3-21R110 is an independent prognostic factor for shorter EFS in early-stage CLL and reduces ibrutinib effectiveness clinically and in vitro.
3 个 Figure · 11 个 KM 面板
Figure 2 Kaplan–Meier plot and risk table estimating time to first treatment in the watch & wait and placebo cohorts of the CLL12 trial. The watch & wait group is depicted in black and the placebo cohort is shown in green. Within each of the two groups, patients expressing IGLV3‐21 R110 (dashed lines) are compared against patients who do not express IGLV3‐21 R110 (solid lines). Hazard ratios (HR) with 95% confidence intervals and P values were calculated using the Cox proportional hazards regression model with the Wald test.
Figure 2 · Panel Time_to_first_treatment_from_diagnosis_months_
Panel Time_to_first_treatment_from_diagnosis_months_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 Kaplan–Meier plots and risk tables estimating event‐free and overall survival in the CLL12 trial. (A , B) EFS (A) and OS (B) of patients from all trial arms. The comparison is carried out between patients expressing IGLV3‐21 R110 (black) and patients not expressing IGLV3‐21 light chains (blue) or expressing IGLV3‐21 G110 (green), taken as one group. (C , D) EFS (C) and OS (D) of patients from the placebo (green) and ibrutinib (blue) arms. Within each treatment arm, patients expressing IGLV3‐21 R110 (dashed lines) are compared against patients who do not express IGLV3‐21 R110 (solid lines). (E , F) EFS (E) and OS (F) of patients from the observational arm. The comparison is carried out between patients expressing IGLV3‐21 R110 (black) and patients not expressing IGLV3‐21 light chains (blue) or expressing IGLV3‐21 G110 (green), taken as one group. Hazard ratios (HR) with 95% confidence intervals and P values were calculated using the Cox proportional hazards regression model with the Wald test. Statistics for all possible pairwise comparisons in (A , B) and (E , F) are provided in Supporting Information S1: Tables S5–S8.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel D
Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel E
Panel E 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel F
Panel F 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 Kaplan–Meier plots and risk tables estimating event‐free and overall survival in the CLL12 trial. (A , B) EFS (A) and OS (B) of patients from all trial arms stratified according to their IGHV mutational status—unmutated (green and blue) or mutated (black and red). Within each of the two groups, patients expressing IGLV3‐21 R110 (green or black, respectively) are compared against patients who do not express IGLV3‐21 R110 (blue or red, respectively). (C , D) EFS (C) and OS (D) of patients from the ibrutinib arm separated according to their IGHV mutational status— unmutated (green and blue) or mutated (black and red). Within each of the two groups, patients expressing IGLV3‐21 R110 (green or black, respectively) are compared against patients who do not express IGLV3‐21 R110 (blue or red, respectively). Hazard ratios (HR) with 95% confidence intervals and P values were calculated using the Cox proportional hazards regression model with the Wald test. Statistics for all possible pairwise comparisons are provided in Supporting Information S1: Tables S9–S12.
Figure 4 · Panel _A_
Panel _A_ 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel _B_
Panel _B_ 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel _C_
Panel _C_ 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel _D_
Panel _D_ 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。